Scholarlink

Introduction <p>Atrial fibrillation (AF) is associated with impaired renal function and chronic kidney disease (CKD). In our study, we aimed to determine the effect of cryoballoon-ablation (CBA) treatment on long-term renal prognosis parameters in paroxysmal-AF patients with CKD.</p> Methods <p>In this retrospective-cohort study, 265-patients with paroxysmal-AF and concomitant CKD (eGFR &lt; 60&#xa0;mL/min/1.73&#xa0;m<sup>2</sup>) between 2013–2023 were identified. 129-patients who underwent CBA for paroxysmal-AF and 101-patients who did not undergo CBA were included. Patients were follow-up for 24-month for adverse renal events. Adverse renal events were defined as (i) ≥ 30% decrease in eGFR, (ii)development of renal failure (eGFR &lt; 15&#xa0;mL/min/1.73<sup>2</sup>) and hemodialysis, iii)hospitalization, and iv)renal-cardiovascular death.</p> Results <p>Patients who did not undergo CBA had higher rates of eGFR decline ≥ 30%, development of renal failure or hemodialysis, hospitalization, and death at follow-up (p &lt; 0.001 for each). During the follow-up of patients who underwent CBA, AF recurrence occurred in 40(31%) cases. The eGFR levels of patients without CBA were significantly decreased at 24-month (32.8 ± 11.6–28.8 ± 10.3, p = 0.034). In patients who underwent CBA, eGFR levels were significantly increased at 24-month (50.4 ± 8.5–66.3 ± 13.1, p &lt; 0.001). Logistic regression analyses was determined that the only parameter that best predicted progression of kidney disease was the presence of CBA (OR = 0.192, %95CI 0.063‒0.590, p = 0.004).</p> Conclusion <p>In AF patients with CKD, CBA was shown to reduce the risk of long-term adverse renal events and improve renal function in accordance with previous studies. Our opinion is that AF patients who develop CKD at the time of initial diagnosis or during follow-up should be followed closely and referred for CBA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Catheter Ablation Reduces Long-Term Adverse Renal Events in Atrial Fibrillation Patients with Chronic Kidney Disease

  • 期刊论文

  • 发表日期：

    2025年7月29日

查看全文
  • Mustafa Lütfullah Ardıç,
  • Hazar Harbalıoğlu,
  • Taner Akı,
  • Mertcan Aksu,
  • Abdullah Eren Çetin,
  • Huseyin Ali Ozturk,
  • Hilmi Erdem Sumbul,
  • Fadime Koca,
  • Hasan Koca,
  • Yahya Kemal Icen,
  • Durmuş Yıldıray Şahin,
  • Mevlut Koc

摘要

Introduction

Atrial fibrillation (AF) is associated with impaired renal function and chronic kidney disease (CKD). In our study, we aimed to determine the effect of cryoballoon-ablation (CBA) treatment on long-term renal prognosis parameters in paroxysmal-AF patients with CKD.

Methods

In this retrospective-cohort study, 265-patients with paroxysmal-AF and concomitant CKD (eGFR < 60 mL/min/1.73 m2) between 2013–2023 were identified. 129-patients who underwent CBA for paroxysmal-AF and 101-patients who did not undergo CBA were included. Patients were follow-up for 24-month for adverse renal events. Adverse renal events were defined as (i) ≥ 30% decrease in eGFR, (ii)development of renal failure (eGFR < 15 mL/min/1.732) and hemodialysis, iii)hospitalization, and iv)renal-cardiovascular death.

Results

Patients who did not undergo CBA had higher rates of eGFR decline ≥ 30%, development of renal failure or hemodialysis, hospitalization, and death at follow-up (p < 0.001 for each). During the follow-up of patients who underwent CBA, AF recurrence occurred in 40(31%) cases. The eGFR levels of patients without CBA were significantly decreased at 24-month (32.8 ± 11.6–28.8 ± 10.3, p = 0.034). In patients who underwent CBA, eGFR levels were significantly increased at 24-month (50.4 ± 8.5–66.3 ± 13.1, p < 0.001). Logistic regression analyses was determined that the only parameter that best predicted progression of kidney disease was the presence of CBA (OR = 0.192, %95CI 0.063‒0.590, p = 0.004).

Conclusion

In AF patients with CKD, CBA was shown to reduce the risk of long-term adverse renal events and improve renal function in accordance with previous studies. Our opinion is that AF patients who develop CKD at the time of initial diagnosis or during follow-up should be followed closely and referred for CBA.